A new method for delivering gene therapy to treat Cystic Fibrosis and other diseases
Official title: A non-viral nanoparticle gene therapy delivery platform for treating Cystic Fibrosis and other diseases
Funded at Ogb5, INC. · NIH-10915092 · Data updated 2026-11-12
This study is working on a new way to deliver gene therapy for Cystic Fibrosis using tiny particles that don’t involve viruses, making it safer and potentially more effective for patients with CF and other lung diseases.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ogb5, INC. NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $320,251 |
| NIH project number | 1R43HL174181-01 |
| Project ID | NIH-10915092 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Cystic Fibrosis who may benefit from advanced gene therapy treatments.
✕Less likely to help
Patients with non-genetic lung diseases or those who do not have Cystic Fibrosis may not receive any benefit from this research.
What this research studies
This research focuses on developing a non-viral nanoparticle platform for delivering gene therapy specifically aimed at treating Cystic Fibrosis (CF) and potentially other chronic lung diseases. The approach utilizes a unique DNA and RNA nanoparticle technology that can carry large genes and includes enhancers to improve gene transfer efficiency to targeted cells. By overcoming the limitations of traditional viral delivery systems, this method aims to provide a safer and more effective way to deliver therapeutic genes directly to the lungs of patients. The research will involve both laboratory experiments and tests in animal models to evaluate the effectiveness of this delivery system.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer gene therapies for patients with Cystic Fibrosis, improving their lung function and overall quality of life.
How similar studies have gone: Previous research has shown promise in using non-viral delivery systems for gene therapy, indicating potential for success with this novel approach.
Where this research is happening
-
Ogb5, INC.
Cincinnati, United States Active
Researchers
- Principal investigator: Sheehan, Colin T. — Ogb5, INC.
- Study coordinator: Sheehan, Colin T.
Related research
Other NIH-funded projects on the same topics.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy
A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.
-
Elastin-like particles to deliver gene therapies for cystic fibrosis
A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.
-
Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS
A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.
-
Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis
A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.
-
Gut microbiome in cystic fibrosis and colorectal cancer risk
Researchers are studying how the gut bacteria in adults with cystic fibrosis influence the development of colorectal cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.